0001209191-19-049534.txt : 20190913
0001209191-19-049534.hdr.sgml : 20190913
20190913185256
ACCESSION NUMBER: 0001209191-19-049534
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190912
FILED AS OF DATE: 20190913
DATE AS OF CHANGE: 20190913
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Shannon James Samuel
CENTRAL INDEX KEY: 0001485417
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35238
FILM NUMBER: 191093459
MAIL ADDRESS:
STREET 1: 28903 NORTH AVENUE PAINE
CITY: VALENCIA
STATE: CA
ZIP: 91355
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Horizon Therapeutics Public Ltd Co
CENTRAL INDEX KEY: 0001492426
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: CONNAUGHT HOUSE, 1ST FLOOR
STREET 2: 1 BURLINGTON ROAD
CITY: DUBLIN
STATE: L2
ZIP: 4
BUSINESS PHONE: 011-353-1-772-2100
MAIL ADDRESS:
STREET 1: CONNAUGHT HOUSE, 1ST FLOOR
STREET 2: 1 BURLINGTON ROAD
CITY: DUBLIN
STATE: L2
ZIP: 4
FORMER COMPANY:
FORMER CONFORMED NAME: Horizon Pharma plc
DATE OF NAME CHANGE: 20140919
FORMER COMPANY:
FORMER CONFORMED NAME: HORIZON PHARMA, INC.
DATE OF NAME CHANGE: 20100520
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-09-12
0
0001492426
Horizon Therapeutics Public Ltd Co
HZNP
0001485417
Shannon James Samuel
C/O HORIZON THERAPEUTICS PLC
CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD
DUBLIN
L2
4
IRELAND
1
0
0
0
Ordinary Shares
2019-09-12
4
M
0
15500
12.19
A
15500
D
Ordinary Shares
2019-09-12
4
S
0
15500
26.5891
D
0
D
Ordinary Shares
2019-09-13
4
M
0
9500
12.19
A
9500
D
Ordinary Shares
2019-09-13
4
S
0
9500
26.19
D
0
D
Ordinary Shares
19272
I
By Trust
Stock Option (Right to Buy)
12.19
2019-09-12
4
M
0
15500
0.00
D
2027-08-01
Ordinary shares
15500
36732
D
Stock Option (Right to Buy)
12.19
2019-09-13
4
M
0
9500
0.00
D
2027-08-01
Ordinary shares
9500
27232
D
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.49 to $26.65 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.18 to $26.25 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The 52,232 shares originally subject to the option vest in 36 equal monthly installments from the date of grant (August 2, 2017).
/s/ Miles W. McHugh, Attorney-in-Fact
2019-09-13